Zydus Lifesciences in pact with Synthon for specialty oncology product in US

Zydus Lifesciences has signed an exclusive agreement with Synthon for the development and commercialisation of a novel oncology product, focusing on reducing pill burden and improving patient compliance. Synthon will handle development and manufacturing, while Zydus will oversee NDA submission and marketing in the US by 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BOCy67s
via IFTTT